Trial Profile
A Multi-Center, Double-Blind, Placebo-Controlled Safety and Preliminary Efficacy Study of IL-1 Trap (Rilonacept) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Rilonacept (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 15 Sep 2014 New trial record